发明申请
US20110207810A1 N1-BENZO[1,3]DIOXOL-5-YLMETHYL-N2-SUBSTITUTED BIGUANIDE DERIVATIVE, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME
失效
N1-BENZO [1,3]二氧杂-5-甲基乙炔-N 2取代的双胍衍生物，其制备方法和含有其的药物组合物
![N1-BENZO[1,3]DIOXOL-5-YLMETHYL-N2-SUBSTITUTED BIGUANIDE DERIVATIVE, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME](/docs/US/2011-08-25/US20110207810A1/abs.jpg.600x600.jpg)
- 专利标题： N1-BENZO[1,3]DIOXOL-5-YLMETHYL-N2-SUBSTITUTED BIGUANIDE DERIVATIVE, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME
- 专利标题（中）： N1-BENZO [1,3]二氧杂-5-甲基乙炔-N 2取代的双胍衍生物，其制备方法和含有其的药物组合物
-
申请号： US13123417申请日： 2009-10-13
-
公开(公告)号： US20110207810A1公开(公告)日： 2011-08-25
- 发明人: Sung Wuk Kim , Sung Soo Jun , Hyae Gyeong Cheon , Kwang Rok Kim , Sang Dal Rhee , Won Hoon Jung , Jong Cheol Lee
- 申请人： Sung Wuk Kim , Sung Soo Jun , Hyae Gyeong Cheon , Kwang Rok Kim , Sang Dal Rhee , Won Hoon Jung , Jong Cheol Lee
- 申请人地址： KR Daejeon-si KR Daejeon
- 专利权人： HANALL BIOPHARMA CO., LTD.,KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY
- 当前专利权人： HANALL BIOPHARMA CO., LTD.,KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY
- 当前专利权人地址： KR Daejeon-si KR Daejeon
- 优先权： KR10-2008-0100171 20081013
- 国际申请： PCT/KR2009/005855 WO 20091013
- 主分类号： A61K31/36
- IPC分类号： A61K31/36 ; C07D317/58 ; A61P3/10 ; A61P35/00 ; A61P3/04 ; A61P9/10
![N1-BENZO[1,3]DIOXOL-5-YLMETHYL-N2-SUBSTITUTED BIGUANIDE DERIVATIVE, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME](/abs-image/US/2011/08/25/US20110207810A1/abs.jpg.150x150.jpg)
摘要：
The present invention provides an N1-benzo[1,3]dioxol-5-ylmethyl-N2-substituted biguanide derivative of formula (I) or a pharmaceutically acceptable salt thereof, a method for preparing same, and a pharmaceutical composition comprising same as an active ingredient. The inventive N1-benzo[1,3]dioxol-5-ylmethyl-N2-substituted biguanide derivative exhibits improved blood glucose level- and lipid level-lowering effects even with a reduced dosage as compared to conventional drugs, and thus, it is useful for preventing or treating diabetes, metabolic syndromes such as insulin-independent diabetes, obesity and atherosclerosis, or a P53 gene defect-related cancer.